Based on this YouTube video's total view count of 424K views and industry-standard rates, the estimated total earning is $297 - $850 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

Explore Pandemic optimism, excess deaths pessimism with 424,844 views, 14,590 likes, and 5,090 comments. Experience the impact of this video content that has captured audience attention.

UK, Zoe symptom study https://health-study.joinzoe.com/data Daily new cases = 106,548 Current symptomatic prevalence = 1,488,559 UK official data https://coronavirus.data.gov.uk Patients admitted, 4,124 down 14% (past 7 days) With covid or for covid? Deaths, 419, down 38% (past 7 days) ONS latest https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsights W/E 23rd August, prevalence 1.64% in England (1 in 60 people) 1.56% in Wales (1 in 65 people) 1.95% in Northern Ireland (1 in 50 people) 1.82% in Scotland (1 in 55 people) Reinfections within the omicron wave 14.6% Alpha, 1.8% Delta, 1% Risk of BA.5 Infection among Persons Exposed to Previous SARS-CoV-2 Variants https://www.nejm.org/doi/full/10.1056/NEJMc2209479?query=TOC&cid=NEJM%20eToc,%20September%201,%202022%20DM1402792_NEJM_Non_Subscriber&bid=1141953912 https://www.nejm.org/doi/suppl/10.1056/NEJMc2209479/suppl_file/nejmc2209479_appendix.pdf Wuhan-Hu-1 55.7% Alpha 58.8% Delta 64.5% BA.1 / BA.2 76.8% (UK, 84.4%) Long covid 2.0 million people in private households in the UK (3.1%) Of those 83% symptoms at least 12 weeks 45% at least one year 22% at least two years Symptoms Fatigue, 62% Shortness of breath, 37% Difficulty concentrating, 33% Muscle ache, 31% Symptoms adversely affected the day-to-day activities 1.5 million people, (73% of those with SRLC) China, millions in Covid lockdown https://www.theguardian.com/world/2022/aug/31/china-places-millions-into-covid-lockdown-again-as-economy-continues-to-struggle China, cases, + 1,717 cases, majority asymptomatic Sporadic cases around China Southern cities of Shenzhen and Guangzhou Northern port city of Dalian Western metropolis of Chengdu to Shijiazhuang Central Hebei province Varying levels of restrictions, closure of venues and restaurants Delayed school reopening Foreign visitors, more than a week of quarantine hotels, sanitary conditions often poor Masking and regular testing, close contacts forcibly transported to field hospitals World Health Organization, China’s policy unsustainable Anbound Research Center President Xi Jinping’s government, Preventing the risk of economic stall should be the priority task Moderna sues Pfizer and BioNTech https://www.washingtonpost.com/business/2022/08/26/moderna-pfizer-covid-lawsuit/?utm_campaign=wp_to_your_health&utm_medium=email&utm_source=newsletter&wpisrc=nl_tyh https://www.documentcloud.org/documents/22266043-moderna-complaint?responsive=1&title=1 MODERNA SUES PFIZER AND BIONTECH FOR INFRINGING PATENTS CENTRAL TO MODERNA'S INNOVATIVE MRNA TECHNOLOGY PLATFORM AUGUST, 26, 2022 https://investors.modernatx.com/news/news-details/2022/Moderna-Sues-Pfizer-and-BioNTech-for-Infringing-Patents-Central-to-Modernas-Innovative-mRNA-Technology-Platform/default.aspx Moderna Chief Legal Officer Shannon Thyme Klinger We believe that Pfizer and BioNTech unlawfully copied Moderna’s inventions, and they have continued to use them without permission Pfizer We are surprised by the litigation given the Pfizer/BioNTech COVID-19 vaccine was based on BioNTech’s proprietary mRNA technology and developed by both BioNTech and Pfizer

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.